Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
highly agglutinative staphylococcin + vinorelbine
- Development stage
- Preclinical
- Lead developer
- Pierre Fabre
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, Intramuscular
01
Overview
This is a combination therapy consisting of highly agglutinative staphylococcin (HAS) and vinorelbine. Vinorelbine is a third-generation vinca alkaloid chemotherapy agent that inhibits microtubule assembly, thereby blocking mitosis and cell division in cancer cells. It is primarily used to treat non-small cell lung cancer (NSCLC) and advanced breast cancer, either alone or in combination with other agents[1][2][3][7]. Highly agglutinative staphylococcin (HAS) is a biologic preparation derived from Staphylococcus aureus cultures; it has been used as an immunomodulator or adjunctive therapy in some regions for various cancers and infections, though its mechanism of action remains incompletely characterized in Western literature. The rationale for combining HAS with vinorelbine may be to enhance anti-tumor immune responses while directly inhibiting tumor cell proliferation.
- Other names
- highly agglutinative staphylococcin and vinorelbineHAS + vinorelbine
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on highly agglutinative staphylococcin + vinorelbine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on highly agglutinative staphylococcin + vinorelbine.